ESC 365 - Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population

ESC Premium Access

Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population

Session: Poster session 5 - Bleeding and LAA occlusion

Topic: Atrial fibrillation (AF)

Speaker: Mr J. Trocio (New York, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Mr Jeffrey Trocio

New York (United States of America)

0 follower

8 more presentations in this session

Establishment and assessment of an LAA occlusion preoperative simulation system based on 3D Printing of 3DTEE imaging

Speaker: Professor R. Guo (Wuhan, CN)

Predictors of cardiovascular events in patients with atrial fibrillation after left atrial appendage closure for stroke prevention in a multicenter analysis.

Speaker: Professor L. Fauchier (Tours, FR)

A comparative study of 3d reconstruction of left atrial appendage model based on ultrasound and CT 3d DICOMdata

Speaker: Professor R. Guo (Wuhan, CN)

Long-term evaluation of safety and efficiency of left atrial appendage (LAA) occlusion

Speaker: Doctor V. Lekesova (Prague, CZ)

Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

Speaker: Miss M. Yee (Boston, US)

Access the full session

Poster session 5 - Bleeding and LAA occlusion

Speakers: Mr J. Trocio, Professor R. Guo, Professor L. Fauchier, Professor R. Guo, Doctor V. Lekesova...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources